top of page

ASGCT 2026: nChroma Bio believes that Hepatitis B is the perfect indication for its epigenetic editing platform. They are already in the clinic and will have initial data this year

  • May 14
  • 1 min read

CEO Jeff Walsh describes the concept of epigenetic editing and why the company chose Hepatitis B, and walks us through the dose escalation schedule that the trial is going through. Plus, work on a virus-like particle delivery method that the company envisions for non-liver delivery.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page